Nektar’s Pain Drug Impresses – Zacks.com

by admin on June 23, 2013

Nektar's Pain Drug Impresses
Zacks.com
Nektar is currently evaluating NKTR-181 in a phase II study for the treatment of chronic pain. The company enrolled around 200 opioid naïve patients, suffering from osteoarthritis of the knee. The patients will be randomized to receive either NKTR-181

View full post on chronic pain – Google News

Previous post:

Next post: